Abetalipoproteinemia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Abetalipoproteinemia, also known as Bassen-Kornzweig syndrome, is a rare autosomal recessive disorder of lipid metabolism characterized by the complete absence of apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, and LDL) in the blood. This leads to severe fat malabsorption, retinal degeneration, neuropathy, and acanthocytosis (abnormal red blood cells). The disease results from mutations in the MTTP gene encoding microsomal triglyceride transfer protein.[@neuroacanthocytosis]
Abetalipoproteinemia was first described independently by Bassen and Kornzweig in 1950, who reported a patient with malabsorption, retinitis pigmentosa, and acanthocytosis. The disease is extremely rare, with an estimated prevalence of approximately 1 in 1,000,000 individuals worldwide.[@acanthocytosis]
The disorder represents a model for understanding the role of apolipoprotein B and [lipid metabolism](/mechanisms/sphingolipid-metabolism) in neurological and retinal function. Early diagnosis and treatment with fat-soluble vitamin supplementation can prevent or delay the neurological and retinal complications.[^7]
Abetalipoproteinemia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Abetalipoproteinemia, also known as Bassen-Kornzweig syndrome, is a rare autosomal recessive disorder of lipid metabolism characterized by the complete absence of apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, and LDL) in the blood. This leads to severe fat malabsorption, retinal degeneration, neuropathy, and acanthocytosis (abnormal red blood cells). The disease results from mutations in the MTTP gene encoding microsomal triglyceride transfer protein.[@neuroacanthocytosis]
Abetalipoproteinemia was first described independently by Bassen and Kornzweig in 1950, who reported a patient with malabsorption, retinitis pigmentosa, and acanthocytosis. The disease is extremely rare, with an estimated prevalence of approximately 1 in 1,000,000 individuals worldwide.[@acanthocytosis]
The disorder represents a model for understanding the role of apolipoprotein B and [lipid metabolism](/mechanisms/sphingolipid-metabolism) in neurological and retinal function. Early diagnosis and treatment with fat-soluble vitamin supplementation can prevent or delay the neurological and retinal complications.[^7]
Abetalipoproteinemia is caused by homozygous or compound heterozygous mutations in the MTTP gene (microsomal triglyceride transfer protein), located on chromosome 4q23. This gene encodes a protein essential for the assembly and secretion of apolipoprotein B-containing lipoproteins in the liver and intestine.[@abetalipoproteinemia]
Over 80 pathogenic variants have been identified, including:
Microsomal triglyceride transfer protein (MTP) plays a crucial role in:
In abetalipoproteinemia, MTP deficiency causes:
| Abnormal Finding | Pathophysiological Consequence |
|-----------------|------------------------------|
| Absent chylomicrons | Fat malabsorption, fat-soluble vitamin deficiency |
| Absent LDL | Reduced [cholesterol](/mechanisms/cerebral-cholesterol-metabolism) delivery to tissues |
| Absent VLDL | Impaired triglyceride transport |
| Acanthocytosis | Altered membrane lipid composition |
| Low vitamin E | Severe antioxidant deficiency in nervous system |
The neurological manifestations result from:
| Feature | Onset | Description |
|---------|-------|-------------|
| Retinitis pigmentosa | 10-20 years | Progressive peripheral vision loss |
| Night blindness | 10-15 years | Often first visual symptom |
| Color vision loss | 20-30 years | Blue-yellow deficiency |
| Central vision loss | 30-40 years | Advanced disease |
| Optic atrophy | 30-40 years | Late complication |
The classic presentation includes:
| Test | Finding |
|------|--------|
| Total cholesterol | Markedly reduced (< 50 mg/dL) |
| LDL cholesterol | Undetectable |
| Triglycerides | Very low (< 10 mg/dL) |
| Apolipoprotein B | Undetectable |
| Vitamin E | Very low (< 1 μg/mL) |
| Vitamin A | Low |
| Vitamin D | Low |
| Vitamin K | Low |
| Liver function tests | May be elevated |
| Condition | Key Distinguishing Features |
|-----------|---------------------------|
| Familial hypobetalipoproteinemia | Partial deficiency, milder phenotype |
| Chylomicron retention disease | Only chylomicrons affected |
| Celiac disease | Malabsorption but normal lipids |
| Cystic fibrosis | Pancreatic insufficiency, normal lipids |
High-dose fat-soluble vitamin supplementation is essential:[^6]
| Vitamin | Daily Dose | Purpose |
|---------|-----------|---------|
| Vitamin E | 100-200 IU/kg | Neuroprotection, antioxidant |
| Vitamin A | 10,000-25,000 IU | Retinal function |
| Vitamin D | 400-1000 IU | Bone health |
| Vitamin K | 5-10 mg | Coagulation |
Vitamin E supplementation has been shown to:
Abetalipoproteinemia is a rare but well-characterized metabolic disorder that serves as an important model for understanding lipoprotein metabolism and its role in neurological and retinal health. The disease highlights the critical importance of fat-soluble vitamins, particularly vitamin E, in maintaining neuronal and retinal function. With early diagnosis and aggressive vitamin supplementation therapy, patients can achieve near-normal life expectancy and quality of life. Ongoing research into gene therapy and MTP modulators offers hope for future treatments that may directly address the underlying metabolic defect. The identification of over 80 pathogenic MTTP variants has improved diagnostic capabilities and enables targeted genetic counseling for affected families.
The study of Abetalipoproteinemia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.